Investors & Media


Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS, disorders. Sage's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus (SRSE) and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. Sage's proprietary chemistry platform has generated multiple new compounds that target GABAA and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.

Investor Inquiries:
Media Inquiries:
$ 44.32 0.00 (0.00%)
Day High: N/A
Day Low:  N/A
Volume:    N/A
4:00 PM ET on
Oct 26, 2016

Delayed ~20 min., by eSignal.